NF Trinity Capital Hong Kong Ltd continued to hold its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, according to its most recent disclosure with the SEC. The fund owned 53,000 shares of the company’s stock at the end of the second quarter. NF Trinity Capital Hong Kong Ltd’s holdings in Teva Pharmaceutical Industries Limited were worth $1,761,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of TEVA. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC bought a new position in Teva Pharmaceutical Industries Limited during the first quarter worth about $123,000. Sterling Investment Advisors Ltd. increased its position in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the last quarter. Finally, Cutler Capital Management LLC bought a new position in Teva Pharmaceutical Industries Limited during the second quarter worth about $133,000. Hedge funds and other institutional investors own 56.04% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 0.48% on Friday, reaching $16.21. 11,590,321 shares of the company’s stock were exchanged. The firm’s market cap is $16.47 billion. The company has a 50 day moving average price of $25.37 and a 200 day moving average price of $30.35. Teva Pharmaceutical Industries Limited has a one year low of $15.85 and a one year high of $52.66.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same period in the previous year, the firm posted $1.25 earnings per share. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Stockholders of record on Tuesday, August 29th will be issued a $0.085 dividend. This represents a $0.34 annualized dividend and a dividend yield of 2.10%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is currently -14.22%.

TRADEMARK VIOLATION NOTICE: “NF Trinity Capital Hong Kong Ltd Continues to Hold Stake in Teva Pharmaceutical Industries Limited (TEVA)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/26/nf-trinity-capital-hong-kong-ltd-continues-to-hold-stake-in-teva-pharmaceutical-industries-limited-teva.html.

TEVA has been the topic of several research reports. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a report on Monday, July 24th. Deutsche Bank AG lowered their price objective on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, May 12th. Royal Bank Of Canada restated an “outperform” rating and set a $37.00 price objective (down previously from $38.00) on shares of Teva Pharmaceutical Industries Limited in a report on Monday, July 17th. Credit Suisse Group downgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $25.00 to $13.00 in a report on Wednesday. Finally, Wells Fargo & Company restated a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a report on Saturday, April 29th. Four equities research analysts have rated the stock with a sell rating, twenty have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited currently has an average rating of “Hold” and an average price target of $35.06.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.